Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

INTRODUCTION: Despite extensive multidisciplinary team (MDT) assessment, some patients have interstitial lung disease (ILD) that is considered unclassifiable (uILD), for which there are currently no approved treatments. This study will assess the efficacy and safety of the antifibrotic pirfenidone i...

Descripción completa

Detalles Bibliográficos
Autores principales: Maher, Toby M, Corte, Tamera J, Fischer, Aryeh, Kreuter, Michael, Lederer, David J, Molina-Molina, Maria, Axmann, Judit, Kirchgaessler, Klaus-Uwe, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Interstitial Lung Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135451/
https://www.ncbi.nlm.nih.gov/pubmed/30233802
http://dx.doi.org/10.1136/bmjresp-2018-000289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135451/
https://www.ncbi.nlm.nih.gov/pubmed/30233802
http://dx.doi.org/10.1136/bmjresp-2018-000289

Ejemplares similares